ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CREO Creo Medical Group Plc

35.25
-0.50 (-1.40%)
Last Updated: 10:14:20
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Creo Medical Group Plc LSE:CREO London Ordinary Share GB00BZ1BLL44 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.40% 35.25 35.00 35.50 35.75 35.25 35.75 197,741 10:14:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 27.17M -26.94M -0.0746 -4.73 127.34M
Creo Medical Group Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker CREO. The last closing price for Creo Medical was 35.75p. Over the last year, Creo Medical shares have traded in a share price range of 23.25p to 49.50p.

Creo Medical currently has 361,251,418 shares in issue. The market capitalisation of Creo Medical is £127.34 million. Creo Medical has a price to earnings ratio (PE ratio) of -4.73.

Creo Medical Share Discussion Threads

Showing 2301 to 2323 of 2400 messages
Chat Pages: 96  95  94  93  92  91  90  89  88  87  86  85  Older
DateSubjectAuthorDiscuss
14/3/2024
10:57
Quality play
bloomberg2
13/3/2024
16:11
Development bank of wales goes from 3.53% to 3.977%

Doesn't quite explain the recent volume but I've know idea why the haven't disclosed the previous position

hatfullofsky
12/3/2024
19:51
Thanks Innovate. We all know that's really disappointing.
hatfullofsky
12/3/2024
18:10
Got a surprisingly quick response from NICE MedTech.
There is as yet ‘no start date’ for the Speedboat evaluation.
My interpretation is that this will not be done before the end of Q3 2024, and may well take longer.

innnovate
12/3/2024
14:11
But it was at an investor conference though. I've never been to one - seemed like 100 PI's, not sure how many of them would be looking to invest or how much, a chance for PR though.
dr biotech
12/3/2024
14:01
I saw that one and indeed it's very informative but it did what it said on the Tin - Technology Update. It was not a trading or business update. Give Chris his technology stage.
hatfullofsky
12/3/2024
13:27
From about 16mins. The whole thing is quite interesting though - he really believes in the tech.

For your video I found the part from around 6mins to be most interesting, he talks about alternative sources of funding.

dr biotech
12/3/2024
13:25
I filled out a form to register as a stakeholder in the NICE process. As such you receive updates on progress and have access to documents. Let’s see if they accept the application.
innnovate
12/3/2024
13:05
This one Dr B ?

On 7min the interviewer asks for next 6 months milestones, Gulliford corrects him and says 6 - 12 months and then DOES NOT mention NICE.

hatfullofsky
12/3/2024
12:55
The CTO said "6 months" in a proactive presentation in Jan. I watched the whole of that one, he didn't seem particularly plugged in to the commercial side and it was a fairly casual comment. Very good from a tech point of view though, for those that want to try and understand what they have.
dr biotech
12/3/2024
12:45
I'm confident your estimations are wrong .....In a good way ?
hatfullofsky
12/3/2024
12:43
Yes I would have expected it to at least have moved to - in development.In this investormeet presentation from 12/09/23 https://www.investormeetcompany.com/meetings/investor-presentation-42113min 30s "NICE Guidance 6 - 12 months in the outside, particularly good for the business"So back in September Gulliford was expecting a March - September 24 timeline
hatfullofsky
12/3/2024
12:20
The company will have little influence over NICE timings. All it can do is provide high quality information in a timely manner.
From the broader NICE database (ie including pharmaceuticals) it appears that some applications predating that of Speedboat for lower GI ESD, remain at the starting gate, while others have progressed, suggesting an overstretched NICE may be prioritizing based anticipated benefits to NHS. Within the MTEP category, all 6 technologies selected by NICE for evaluation remain at the ‘awaiting development’ stage. One MTEP application (07MAR2023) pre-dates speedboat (25MAY2023).
It could be a while yet before NICE guidance is generated for Speedboat.

innnovate
12/3/2024
11:16
Is that 1,000,000 shares deal a buy or sell? Anyone know?
pacsltd
12/3/2024
10:26
I'm confident your estimations are wrong
master investor
12/3/2024
09:45
That is disappointing - assuming the website it accurate (and there is no obvious reason to doubt it). Please let us know what they say. I'd hope the delay is on the NICE side.
dr biotech
12/3/2024
08:32
"A Complete failure from the company" !!!
Have you any idea how incompetent the NHS/NICE people really are ?!
How many NICE applications have you managed to attain?

pacsltd
12/3/2024
08:29
I've had to re-asses my timeline on NICE



CREO is still at - Awaiting Development (since 25/05/23)

According to



I'm estimating we could be up to 30 weeks away which would be incredibly disappointing and a complete failure from the company.

In Development Wk 8
In Consultation Wk 24
Published Wk 38

I'll also contact the company

@Innovate - Can you validate this please

hatfullofsky
09/3/2024
11:42
Yes big volumes with price holding up thus far.
From limited access to trade log I see a large 3.5m sell late Friday.
‘08Mar-24 16:54:49 37.00 3,550,000 Sell’

innnovate
09/3/2024
01:01
Now what about this current volume ? NICE volume ? ;-)
hatfullofsky
09/3/2024
01:01
It was on a video shortly after the announcement, I'll dig it out
hatfullofsky
07/3/2024
13:50
@hat: re NICE approached CREO
Do you have a reference for this?
My understanding is that NICE selected Creo tech for an in depth review, but Creo will have first submitted data package describing lower-GI ESD use case for initial high-level assessment at NICE (see release of 01.06.2023). Not every application received by NICE will be reviewed in depth. I’m optimistic NICE will conclude positively, but it might easily ask for more data if the review panel is not fully convinced.

innnovate
07/3/2024
11:55
Canaccird selling ? Reason for pruce still being supressed?
billthebank
Chat Pages: 96  95  94  93  92  91  90  89  88  87  86  85  Older

Your Recent History

Delayed Upgrade Clock